LON:COIL Roquefort Therapeutics (COIL) Share Price, News & Analysis GBX 8.50 +0.90 (+11.84%) As of 09:58 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and Trends About Roquefort Therapeutics Stock (LON:COIL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Roquefort Therapeutics alerts:Sign Up Key Stats Today's Range 7.50▼ 8.5050-Day Range 7.49▼ 10.5052-Week Range 6.75▼ 12.50Volume156,529 shsAverage Volume204,342 shsMarket Capitalization£36.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals. https://coiledplc.com/ Read More Receive COIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COIL Stock News HeadlinesRoquefort Therapeutics' (COIL) "House Stock" Rating Reaffirmed at Shore Capital GroupSeptember 21 at 6:12 AM | americanbankingnews.comCoiled Therapeutics PLCApril 1, 2026 | barrons.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 21 at 1:00 AM | Stansberry Research (Ad)Roquefort springs over to AIM from Main Market as Coiled TherapeuticsMarch 27, 2026 | lse.co.ukCoiled Therapeutics' Dr Sotirios Stergiopoulos on Roquefort RTO, AO-252 cancer trial updateMarch 9, 2026 | uk.finance.yahoo.comSmall cap idea: Why this £40m bet on an emerging cancer treatment may be perfectly timedMarch 9, 2026 | msn.comWhy this £40m bet on an emerging cancer treatment may be perfectly timedMarch 4, 2026 | uk.finance.yahoo.comRoquefort Therapeutics to acquire cancer drug licence in £32m RTO deal and raise £8.5mMarch 2, 2026 | uk.finance.yahoo.comSee More Headlines COIL Stock Analysis - Frequently Asked Questions How have COIL shares performed this year? Roquefort Therapeutics' stock was trading at GBX 12 at the beginning of the year. Since then, COIL shares have decreased by 29.2% and is now trading at GBX 8.50. How were Roquefort Therapeutics' earnings last quarter? Roquefort Therapeutics plc (LON:COIL) issued its earnings results on Wednesday, May, 6th. The company reported ($2.19) earnings per share for the quarter. Roquefort Therapeutics had a negative trailing twelve-month return on equity of 18.71% and a negative net margin of 57,057.07%. When did Roquefort Therapeutics' stock split? Roquefort Therapeutics's stock reverse split on the morning of Friday, March 27th 2026.The 1-10 reverse split was announced on Friday, March 27th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Roquefort Therapeutics? Shares of COIL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Roquefort Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Roquefort Therapeutics investors own include Vislink Technologies (XGTI), AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX) and Abacus Health Products (ABAHF). Company Calendar Last Earnings5/06/2026Today9/21/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:COIL Previous SymbolLON:ROQ CIKN/A Webwww.roquefortinvest.com Phone44 20 3290 9339FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (21.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£1.52 million Net Margins-57,057.07% Pretax MarginN/A Return on Equity-18.71% Return on Assets-15.86% Debt Debt-to-Equity Ratio8.18 Current Ratio0.63 Quick Ratio3.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 5.69 per share Price / Cash Flow1.49 Book ValueGBX 3.82 per share Price / Book2.23Miscellaneous Outstanding Shares426,791,000Free FloatN/AMarket Cap£36.28 million OptionableNot Optionable Beta0.05 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (LON:COIL) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
